Natural History of Amyloid Deposition in Adults With Down Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01303133

Enrollment

Registered

2011-02-24

Start date

2009-08-31

Completion date

2018-03-31

Last updated

2019-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Down Syndrome

Keywords

beta amyloid, Down Syndrome, Alzheimer's Disease

Brief summary

The primary objective of this study is to assess the presence of amyloid in non-demented/functionally stable adults with DS as a function of age, dividing the sample into amyloid-positive and amyloid-negative groups. We will also obtain baseline cognitive measures across a range of areas that are often affected by AD.

Detailed description

Specific Aim 1: To assess and compare amyloid deposition (with PiB PET) in non-demented/functionally stable adults with DS across three age cohorts (30-39, 40-49, and \>50 years of age). Primary Hypothesis 1: At initial assessment, there will be a significantly higher prevalence of amyloid-positive (PiB+) subjects in each succeeding age cohort. In addition, we will test the following secondary hypothesis: Secondary Aim 1: To compare the presence or absence of the apolipoprotein-E4 allele to the retention of PiB in various brain areas of the DS subjects. Secondary Hypothesis 1: At baseline, subjects who carry at least one Apolipoprotein-E4 (ApoE4) allele will show a higher prevalence of being PiB+.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

30 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Participant IQ at least 47 (based upon Stanford-Binet V Abbrev. Test Battery) 2. Participant at least 30 years of age 3. DSDS score indicating participant is asymptomatic for AD 4. Reliable caregiver who is capable of providing correct information about the participant's clinical symptoms and history 5. Agreement of caregiver and clinician that participant is able to cooperate with the protocol tasks 6. Participant has provided assent (or consent) and/or parent/caregiver has provided informed consent

Exclusion criteria

1. Participant is non-verbal or has extremely limited language skills 2. Score within the symptomatic range on the DSDS 3. Any significant disease or unstable medical condition that could affect neuropsychological testing 4. Any problems with vision or hearing that could affect neuropsychological testing 5. Participants in whom MRI is contraindicated 6. Claustrophobia or prior failed experiences of completing MRI scans or blood draws 7. Participant is pregnant or breast feeding 8. History or other evidence of severe illness or other condition that would make the participant, in the opinion of the investigator, unsuitable for the study?

Design outcomes

Primary

Measure	Time frame	Description
Amyloid deposition	every 36 months for 9 years	Obtained via PiB PET scan

Countries

United States

Outcome results